11
Module 11 of 12
Wound Care & Scar Management
By Dr. Yehonatan Kaplan (M.D., Fellow ACMS)Published: 2026-03-10Updated: 2026-03-13Reviewed: 2026-03-13
Learning Objectives
- Describe the three overlapping phases of wound healing and the key cellular mediators at each stage
- Identify local and systemic factors that impair wound healing and strategies to mitigate them
- Design a postoperative wound care protocol including dressing selection and patient instructions
- Determine optimal suture removal timing based on anatomic location and closure type
- Implement evidence-based scar prevention strategies including silicone and photoprotection
- Classify and manage hypertrophic scars and keloids with appropriate treatment algorithms
Wound Healing Biology
Cutaneous wound healing proceeds through three overlapping phases: inflammatory, proliferative, and remodeling. Each phase is driven by distinct cellular populations and molecular mediators. Understanding this sequence is essential for the dermatologic surgeon because surgical technique, wound care decisions, and complication management all depend on optimizing conditions at each stage.
Inflammatory Phase (0–48 Hours)
The inflammatory phase begins within minutes of tissue injury and lasts 24–48 hours. Hemostasis is the immediate priority: platelet aggregation and fibrin deposition form the initial wound matrix, which serves as a scaffold for subsequent cell migration.
Platelets are the first responders, releasing chemotactic factors (PDGF, TGF-β) that recruit inflammatory cells and producing fibrin and fibronectin that form the provisional clot matrix. Neutrophils are the first immune cells to arrive at the wound site, peaking at 24–48 hours. They perform tissue debridement through proteolytic enzyme release and clear bacteria through phagocytosis and reactive oxygen species.
Macrophages arrive next and are the critical orchestrators of wound healing. They phagocytose debris and bacteria, secrete growth factors (PDGF, FGF, VEGF, TGF-β) that stimulate fibroblast proliferation and extracellular matrix production, and mediate the transition from the inflammatory to the proliferative phase. Macrophage depletion experiments demonstrate that wounds cannot progress beyond the inflammatory phase without macrophage signaling.
Key Points
- Neutrophils are the FIRST immune cells to arrive; macrophages are CRITICAL for transitioning to the proliferative phase
- Macrophage-derived growth factors (PDGF, TGF-β, VEGF) are indispensable for fibroblast recruitment and angiogenesis
Clinical Pearls
- Prolonged inflammation (infection, foreign body, tissue necrosis) delays the transition to the proliferative phase and impairs healing. Meticulous hemostasis and debridement during surgery directly support this transition.
Proliferative Phase (Days 5–30)
The proliferative phase begins around day 5 and lasts approximately one month. Three concurrent processes characterize this phase: re-epithelialization, fibroplasia with granulation tissue formation, and wound angiogenesis.
Re-epithelialization begins within hours of injury as keratinocytes at the wound edge lose their desmosomal attachments and begin migrating across the wound surface in a ‘leapfrog’ pattern, guided by matrix metalloproteinases (MMPs). This process is accelerated in moist wound environments and retarded by desiccation and eschar formation.
Fibroplasia involves fibroblast migration into the wound along the provisional fibronectin matrix. Fibroblasts deposit Type III collagen, forming granulation tissue. Some fibroblasts differentiate into myofibroblasts expressing α-smooth muscle actin, which generate contractile forces that reduce wound size by up to 40–80% (wound contraction). Concurrent angiogenesis, driven by VEGF and FGF, establishes new blood vessel networks within the granulation tissue.
Key Points
- Type III collagen is the predominant collagen produced during the proliferative phase
- Moist wounds re-epithelialize 30–50% faster than dry wounds. This is the biological basis for occlusive dressing protocols
- MMPs are essential for keratinocyte migration during re-epithelialization
Remodeling Phase (3 Weeks to 12–15 Months)
The remodeling phase begins around 3–4 weeks after injury and continues for 12–15 months. During this extended phase, the wound transitions from metabolically active granulation tissue to a relatively acellular, collagen-dense scar.
The hallmark event is the replacement of Type III collagen with Type I collagen, which is stronger and more organized. Matrix metalloproteinases (MMPs) and their inhibitors (TIMPs) regulate this turnover. Collagen fibers progressively organize along lines of mechanical tension, increasing wound tensile strength.
Wound tensile strength follows a predictable trajectory: approximately 3–5% of normal skin strength at 1 week, 20% at 3 weeks, 50–60% by 3 months, and a maximum of 70–80% of original skin strength. Wounded skin never regains 100% of its original tensile strength.
Key Points
- Scar tissue reaches a maximum of only 70–80% of the tensile strength of uninjured skin. This is permanent.
- Type III collagen (proliferative phase) is replaced by Type I collagen (remodeling phase) through MMP-mediated turnover
Clinical Pearls
- The 12–15 month remodeling timeline is why scar revision should be delayed at least 12 months — the scar may continue to improve with conservative measures.
Factors Affecting Wound Healing
Multiple local and systemic factors can impair wound healing by disrupting one or more phases of the repair cascade.
Clinical Pearls
- The Mohs surgeon should assess wound healing risk factors preoperatively. Tobacco use, diabetes, chronic steroids, and anticoagulation are the most commonly encountered impairments in the dermatologic surgery population.
| Factor | Effect on Healing | Clinical Relevance |
|---|---|---|
| Tobacco use | Vasoconstriction reduces tissue oxygenation; impairs neutrophil and macrophage function; reduces collagen synthesis | Smoking cessation for at least 4 weeks before elective surgery is recommended. Nicotine replacement also impairs healing. |
| Diabetes mellitus | Impaired neutrophil function, prolonged inflammation, defective angiogenesis, peripheral neuropathy | Tight glycemic control perioperatively (HbA1c < 8%) reduces wound complications |
| Immunosuppression | Reduced inflammatory response and impaired macrophage function | Consider holding or reducing immunosuppressants perioperatively when feasible (with prescriber coordination) |
| Malnutrition (protein, vitamin C, zinc) | Impaired collagen synthesis (vitamin C), reduced immune function (protein, zinc) | Supplement vitamin C (500 mg/day) and zinc (220 mg/day) in deficient or malnourished patients |
| Chronic corticosteroids | Suppress inflammatory phase; reduce fibroblast proliferation and collagen synthesis | Topical vitamin A can partially reverse steroid-induced wound healing impairment |
| Radiation history | Fibrosis of microvasculature; reduced fibroblast proliferation; chronic tissue hypoxia | Previously irradiated tissue has permanently impaired healing capacity. Plan reconstructions accordingly. |
| Tissue hypoxia / poor perfusion | Inadequate oxygen delivery for cell proliferation and collagen cross-linking | Avoid excessive wound tension; consider hyperbaric oxygen for refractory wounds in ischemic tissue |
Chronic Wounds
A chronic wound is defined as one that has not healed by 12 weeks or fails to reduce in size by 50% within 4 weeks. Chronic wounds are arrested in the inflammatory or proliferative phase. Pathologic features include elevated MMP levels that degrade new matrix as quickly as it is deposited, defective fibroblast infiltration, persistent biofilm-associated infection, and perivascular fibrin cuffs that impair oxygen delivery. Management focuses on addressing the underlying cause (vascular insufficiency, pressure, infection), debridement of nonviable tissue, moisture balance through appropriate dressings, and topical antimicrobial therapy when clinically infected.
Key Points
- Chronic wounds are arrested in the inflammatory or proliferative phase, not the remodeling phase
- Elevated MMPs in chronic wounds destroy new ECM, creating a self-perpetuating cycle of tissue breakdown
- Biofilm (not planktonic bacteria) is the predominant form of infection in chronic wounds and requires physical debridement, not antibiotics alone
Postoperative Wound Care
Proper wound care in the first 2–4 weeks after dermatologic surgery is critical for optimal healing. The goals are to maintain a moist wound environment, prevent infection, minimize edema and hematoma, and protect the repair from mechanical disruption.
Pressure Dressing (First 24–48 Hours)
Immediately after wound closure, a pressure dressing is applied to minimize dead space, reduce the risk of hematoma formation, and immobilize the repair.
Components of a standard pressure dressing:
• Non-adherent contact layer (petrolatum gauze or Adaptic) directly over the wound
• Absorbent gauze layer to wick exudate
• Conforming wrap or tape providing gentle compression
The pressure dressing is typically left in place for 24–48 hours. The patient is instructed to keep the dressing clean and dry, avoid strenuous activity, and sleep with the head elevated (for facial wounds) to reduce edema.
For flap repairs, bolster dressings provide additional immobilization during the critical first 48–72 hours. For skin grafts, the bolster remains for 5–7 days.
Key Points
- The pressure dressing serves three functions: hemostasis (compression), immobilization (prevents shearing), and protection (barrier to contamination)
- Head elevation to 30–45 degrees for the first 48 hours significantly reduces facial edema and ecchymosis after Mohs surgery
Moist Wound Healing Protocol
After pressure dressing removal, the wound transitions to a moist healing protocol. Evidence consistently demonstrates that moist wound environments accelerate re-epithelialization by 30–50% compared to dry healing, reduce pain, and produce superior cosmetic outcomes.
Standard moist wound care protocol:
1. Gentle cleansing: wash the wound with mild soap and water or dilute hydrogen peroxide (1:1 with water) once or twice daily. Avoid aggressive scrubbing.
2. Apply a thin layer of plain white petrolatum (Vaseline) or antibiotic ointment to the wound surface. Petrolatum is preferred. It provides equivalent moisture retention without the risk of contact dermatitis associated with topical antibiotics (especially neomycin and bacitracin).
3. Cover with a non-adherent dressing or adhesive bandage.
4. Repeat the clean-apply-cover cycle once or twice daily until suture removal or full re-epithelialization.
Clinical Pearls
- Plain petrolatum is the evidence-based standard for postoperative wound care. Multiple RCTs show equivalent infection rates compared to topical antibiotics, with significantly lower rates of allergic contact dermatitis
- Neomycin is the most common cause of contact dermatitis from topical antibiotics in postoperative wounds. Avoid routine use; if an antibiotic is desired, mupirocin is a better choice
Important Warnings
- Do NOT allow wounds to dry out and form a hard eschar. Dry crusting impedes epithelial cell migration across the wound surface and delays healing by days to weeks
Dressing Selection
The choice of wound dressing depends on the wound type, location, exudate level, and whether the wound is healing by primary intention (sutured) or secondary intention (open).
Clinical Pearls
- For most sutured Mohs wounds, simple petrolatum + bandage is sufficient. Advanced dressings are reserved for secondary intention wounds or complex closures
- Hydrocolloid dressings are excellent for concave secondary intention wounds (medial canthus, conchal bowl). They conform to the wound contour and require less frequent changes
| Dressing Type | Best For | Key Properties | Change Frequency |
|---|---|---|---|
| Petrolatum gauze (Adaptic) | Sutured wounds, graft sites | Non-adherent; maintains moisture; inexpensive | Daily |
| Adhesive bandage + petrolatum | Small sutured wounds | Convenient; good patient compliance | Daily |
| Foam dressing (Mepilex) | Secondary intention wounds with moderate exudate | Absorbent; atraumatic removal; comfortable | Every 2–3 days |
| Hydrocolloid (DuoDERM) | Shallow secondary intention wounds | Self-adhesive; maintains moist environment; waterproof | Every 3–5 days |
| Alginate (Kaltostat) | Heavily exudative wounds | Highly absorbent; hemostatic; conforms to wound bed | Daily to every 2 days |
| Silicone mesh (Mepitel) | Fragile skin, graft sites, pediatric patients | Ultra non-adherent; can be left in place under secondary dressing | Every 5–7 days |
Suture Removal & Activity Restrictions
Suture removal timing balances two competing risks: removing too early risks wound dehiscence, while leaving sutures too long increases scarring from suture track marks and increases infection risk.
Suture Removal Timing by Location
The optimal time for suture removal depends on the anatomic location (blood supply and mechanical stress), the type of closure, and whether deep (buried) sutures were placed to support the wound.
Key Points
- On the face, deep buried sutures carry the wound tension. Epidermal sutures can be removed early (5–7 days) because they serve primarily for wound edge eversion and alignment, not structural support
- On the lower extremity, especially the pretibial area, sutures should remain for at least 14 days due to poor vascularity and high dehiscence risk
- Running subcuticular sutures can remain longer (7–14 days on face) without causing track marks because they do not cross the skin surface
| Location | Suture Removal (Days) | Rationale |
|---|---|---|
| Eyelid | 5–7 | Excellent blood supply; thin skin shows suture marks quickly |
| Face (general) | 5–7 | Rich vascular supply allows early removal; deep sutures bear tension |
| Ear | 7–10 | Moderate blood supply; cartilage framework limits tension |
| Scalp | 7–14 | Excellent blood supply but high tension from galea; staples may be used |
| Neck | 7–10 | Good blood supply; moderate tension from platysma |
| Trunk | 10–14 | Moderate blood supply; significant mechanical stress |
| Extremities (upper) | 10–14 | Moderate blood supply; moderate tension from movement |
| Extremities (lower) | 14–21 | Poor blood supply (especially pretibial); high tension; slow healing |
| Hands and feet | 10–14 | Constant mechanical stress from use; thick skin |
Activity Restrictions
Postoperative activity restrictions are designed to prevent wound complications during the critical early healing phase.
• First 24–48 hours: Strict rest. No bending, lifting, or straining. Head elevation for facial wounds. No alcohol (increases bleeding risk).
• Days 2–7: Light activities of daily living permitted. No exercise, heavy lifting (>10 lbs), or activities that increase blood pressure or heart rate.
• Days 7–14: Gradually resume light exercise (walking). Avoid swimming, contact sports, and activities that place direct stress on the wound.
• After suture removal: Progressive return to full activity. Continue sun protection of the scar for 6–12 months.
Important Warnings
- Premature vigorous exercise is a common cause of postoperative hematoma and dehiscence. Patients frequently underestimate the importance of activity restrictions, especially for facial wounds that ‘feel fine’
Scar Prevention & Management
Scar optimization begins at the time of surgery (wound closure technique) and continues for 6–12 months postoperatively. The key modifiable factors are wound tension, sun exposure, and early scar intervention.
Evidence-Based Scar Prevention
Scar prevention strategies should be initiated immediately after suture removal and continued for a minimum of 3–6 months:
Clinical Pearls
- Silicone is the only topical scar prevention intervention with strong RCT evidence. Both sheeting and gel formulations are effective; the choice depends on patient preference and scar location
- Paper tape across the scar line for 8–12 weeks after suture removal is a simple, inexpensive intervention that significantly reduces scar width on the trunk and extremities by off-loading mechanical tension
- The most important scar prevention measure is meticulous surgical technique. Wound edge eversion, layered tension-free closure, and appropriate suture selection have more impact than any topical intervention
| Intervention | Mechanism | Evidence Level | When to Start |
|---|---|---|---|
| Silicone sheeting / gel | Hydrates stratum corneum; reduces TEWL; modulates fibroblast activity | Strong (multiple RCTs, Cochrane review) | After full re-epithelialization (1–2 weeks post suture removal) |
| Paper tape / wound strips | Reduces mechanical tension on healing scar; prevents scar widening | Moderate (RCTs showing benefit for trunk and extremity scars) | Immediately after suture removal; continue 8–12 weeks |
| Sun protection (SPF 30+) | Prevents UV-induced hyperpigmentation of immature scar | Strong (consensus recommendation) | Immediately; continue 6–12 months |
| Scar massage | Disrupts collagen cross-links; improves scar pliability | Weak-moderate (limited RCTs; widely practiced) | After full wound maturation (2–4 weeks post-op) |
| Onion extract (Mederma) | Anti-inflammatory; may reduce collagen production | Weak (inconsistent RCT results) | After re-epithelialization; limited evidence of benefit |
Hypertrophic Scars & Keloids
Hypertrophic scars and keloids represent excessive fibroproliferative responses to wound healing. Understanding the distinction is critical for treatment selection and prognosis.
| Feature | Hypertrophic Scar | Keloid |
|---|---|---|
| Borders | Confined to original wound margins | Extends BEYOND original wound margins |
| Timeline | Develops within weeks; typically regresses over 12–24 months | May develop months to years after injury; does not spontaneously regress |
| Risk factors | Wound tension, infection, delayed healing | Genetic predisposition (African, Asian, Hispanic descent); ear, chest, shoulder location |
| Histology | Organized type III collagen parallel to skin surface | Disorganized thick type I and III collagen bundles (keloidal collagen) |
| Recurrence after excision | Low (∼10%) | Very high (50–80% without adjuvant therapy) |
| Symptoms | Mild pruritus; usually asymptomatic | Pruritus, pain, tenderness common |
Treatment Algorithm
Treatment of hypertrophic scars and keloids follows a stepwise approach, escalating from conservative measures to procedural interventions:
Key Points
- Intralesional corticosteroids (TAC) remain the first-line treatment for both hypertrophic scars and keloids. Response rates of 50–70% for flattening and symptom relief
- For keloids, a combined approach (excision + radiation or excision + TAC injections) offers the best outcomes, with recurrence rates as low as 10–20%
Important Warnings
- Never excise a keloid without planned adjuvant therapy. Surgical excision alone has a 50–80% recurrence rate and often produces a LARGER keloid than the original
- Intralesional TAC can cause dermal atrophy and hypopigmentation. Use the lowest effective concentration and avoid injecting into surrounding normal skin
| Treatment | Mechanism | Best For | Key Details |
|---|---|---|---|
| Intralesional triamcinolone (TAC) | Suppresses fibroblast proliferation and collagen synthesis | First-line for both hypertrophic scars and keloids | 10–40 mg/mL; inject into scar at 4–6 week intervals; 3–6 sessions typical |
| Silicone sheeting/gel | Hydration and occlusion reduce fibroblast activity | Adjunct for both; first-line prevention | Apply 12–24 hours/day for 3–6 months minimum |
| Pressure therapy | Reduces blood flow to scar; limits collagen deposition | Ear keloids (pressure earring); large hypertrophic scars | Custom compression garment worn 23 hours/day for 6–12 months |
| 5-Fluorouracil (5-FU) intralesional | Inhibits fibroblast proliferation | Resistant keloids; combined with TAC for refractory scars | 50 mg/mL; inject alone or mixed with TAC; weekly for 8–12 sessions |
| Cryotherapy | Induces vascular damage and tissue necrosis within scar | Small keloids; combined with intralesional steroids | Contact or intralesional cryotherapy; 2–3 freeze-thaw cycles |
| Surgical excision + adjuvant therapy | Debulks scar mass; adjuvant prevents recurrence | Keloids failing medical therapy | MUST combine with adjuvant (TAC, radiation, or 5-FU). Excision alone has 50–80% recurrence |
| Radiation (superficial RT) | Destroys fibroblasts in wound bed post-excision | Refractory keloids after surgical excision | Delivered within 24–48 hours of excision; 12–20 Gy in 3–4 fractions |
Related Tools & Resources
References
- [1]Martin P, Nunan R. Cellular and molecular mechanisms of repair in acute and chronic wound healing. Br J Dermatol. 2015. doi:10.1111/bjd.13954 PMID: 26175283
- [2]Guo S, DiPietro LA. Factors affecting wound healing. J Dent Res. 2010. doi:10.1177/0022034509359125 PMID: 20139336
- [3]Kantor J. The evidence-based approach to wound care in dermatologic surgery. J Am Acad Dermatol. 2019. doi:10.1016/j.jaad.2018.09.025
- [4]Gold MH, McGuire M, Mustoe TA, et al. Updated international clinical recommendations on scar management: Part 2:algorithms for scar prevention and treatment. Dermatol Surg. 2014. doi:10.1097/DSS.0000000000000050
- [5]Zitelli JA. Wound healing by secondary intention. A cosmetic appraisal. J Am Acad Dermatol. 1983. doi:10.1016/S0190-9622(83)70196-2
- [6]Robinson JK, Hanke CW, Siegel DM, Fratila A. Surgery of the Skin: Procedural Dermatology, 3rd Edition. Elsevier. 2019.
About This Article
Author: Dr. Yehonatan Kaplan, M.D., Fellow ACMS
Last Medical Review:
Audience: Dermatologic Surgeons
Clinic: Kaplan Clinic · DermUnbound Research Program